A new delivery method can give an established drug a fresh commercial story. Now, CMS is changing the rules. CMS’s latest Medicare decision could reshape pharma formulation strategy, especially for drugs that use an added ingredient to enable a different delivery method. Will a new injection still create a fresh pricing runway? For pharmaceutical marketers, the answer may be more complicated than expected.
Table of Contents
- What CMS Changed for Fixed-Combination Drugs
- Why CMS Is Changing the Rules for Drug Reformulations
- How Brands Can Prove Value Beyond a New Route
- What a Stronger Follow-On Formulation Plan Looks Like
- Conclusion
- Frequently Asked Questions
What CMS Changed for Fixed-Combination Drugs
On November 5, 2026, the Centers for Medicare & Medicaid Services finalized a rule governing Medicare drug price negotiations for 2029 and beyond. The rule takes effect December 5, 2026, with the next selection cycle beginning in 2027. Previously, CMS generally treated drugs with distinct combinations of active ingredients as separate products for negotiation purposes. However, the new policy creates a narrow exception.
CMS may group products from the same FDA application holder when they share an active component and an added ingredient enables another route of administration. For example, a biologic combined with hyaluronidase to allow subcutaneous injection instead of intravenous infusion may fall under this policy. In such cases, separate FDA approvals do not necessarily mean separate Medicare negotiation treatment.
As a result, a negotiated maximum fair price could apply to both formulations if the qualifying drug is selected. Importantly, this does not mean every reformulated medication automatically becomes subject to negotiation. The policy addresses specific fixed-combination products that meet CMS’s criteria.
Why CMS Is Changing the Rules for Drug Reformulations
This policy challenges a familiar commercial assumption: a new formulation can create a fresh Medicare negotiation timeline. Under the revised framework, some manufacturers may lose that separation even after investing in product development, regulatory approval, and launch preparation.
CMS’s concern centers on whether manufacturers could shift patients toward newer formulations to avoid negotiated prices on older products. Consequently, the agency is treating certain follow-on formulations as part of the same qualifying single-source drug.
Consider Keytruda Qlex and Opdivo Qvantig, two FDA-approved subcutaneous products that combine an established cancer therapy with an ingredient that supports injection under the skin. These products illustrate the type of delivery innovation involved, although their approvals do not establish a specific CMS grouping determination.
For brand teams, the commercial implications deserve attention. A formulation that improves convenience may still offer real value, but its financial projections should not depend on an assumed extension of Medicare pricing flexibility.
As an earlier Pharma Marketing Network analysis of the Inflation Reduction Act timeline explains, Medicare negotiation timing already influences pharmaceutical launch investments and lifecycle planning.
Now, brand teams must weigh the original drug’s Medicare negotiation timeline against the clinical and commercial value of its follow-on formulation. In addition, they need to consider how pricing changes might affect payer relationships, market access, and long-term brand positioning.
How Brands Can Prove Value Beyond a New Route
A shorter administration can make a meaningful difference for patients, healthcare professionals, and busy treatment centers. However, a more convenient delivery method does not automatically mean better clinical outcomes.
Brand teams should therefore focus on what a new formulation actually changes for the people using it. Does it reduce time spent in a treatment chair? Could it simplify appointment scheduling or free up infusion capacity? Might it reduce travel burdens or help patients fit treatment around work and family responsibilities?
These questions can help companies identify benefits worth measuring and communicating. For example, studies may examine administration time, patient preferences, staff workload, healthcare resource use, and treatment completion where appropriate.
Additionally, marketers must distinguish demonstrated benefits from expected advantages. A convenient injection may improve the treatment experience without proving superior effectiveness or safety.
The FDA’s approval of Keytruda Qlex offers an example of the clinical evaluation supporting a change in administration route. Such evidence matters because healthcare professionals and payers need reliable information when evaluating treatment options.
CMS also declined to create a special grouping exception for products offering genuine improvements in safety, effectiveness, adherence, or delivery. Therefore, demonstrated patient benefits remain important commercially, but they do not automatically establish separate Medicare negotiation treatment.
Brand teams should also make sure their marketing claims reflect proven benefits, without suggesting that greater convenience automatically means better clinical outcomes.
What a Stronger Follow-On Formulation Plan Looks Like
For pharmaceutical companies, the new CMS policy makes earlier coordination especially important. Development, regulatory, medical affairs, market access, and commercial teams should evaluate potential Medicare implications before committing to a follow-on formulation strategy.
First, companies should determine whether a proposed formulation could meet CMS’s fixed-combination grouping criteria. Next, financial models should compare outcomes with and without separate Medicare negotiation treatment. This approach can reveal commercial risks that might otherwise remain hidden until later in development.
However, Medicare pricing should not be the only factor shaping the business case. A new formulation may still improve the treatment experience, support clinical workflows, or address practical barriers to care.
Brands should identify these potential benefits early and establish ways to measure them. For example, clinical development plans might include relevant patient-reported experiences, administration time, or healthcare resource use. Meanwhile, commercial teams can evaluate how those findings may influence physician education, payer discussions, and positioning.
This approach also connects with Pharma Marketing Network’s discussion of label expansion and pharmaceutical lifecycle growth, where meaningful differentiation helps established brands remain relevant.
Additionally, digital education can help communicate approved product information to healthcare professionals. Partners such as eHealthcare Solutions may support targeted pharmaceutical marketing efforts that reach appropriate professional audiences.
Ultimately, the business case for a follow-on formulation should rest on measurable patient and clinical benefits, rather than an assumed advantage under Medicare’s pricing rules.
Conclusion
CMS has not banned reformulations or declared different delivery methods clinically interchangeable. Instead, the agency has narrowed the circumstances in which certain fixed-combination products receive separate treatment under Medicare negotiation beginning with the 2029 price year.
For pharmaceutical marketers, that change raises the importance of credible evidence, thoughtful lifecycle planning, and clear communication. A new formulation can still offer meaningful advantages. However, brands increasingly need to demonstrate those advantages through measurable clinical, workflow, and patient-experience benefits rather than relying on a fresh pricing timeline.
Frequently Asked Questions
Does the CMS rule apply to every new drug formulation?
No. The policy targets specific fixed-combination products where an additional active component enables an alternative route of administration and the products share the same FDA application holder.
When does the new Medicare negotiation policy take effect?
The final rule becomes effective December 5, 2026. Its negotiation framework applies to prices beginning in 2029, with the fourth selection cycle taking place in 2027.
Can a subcutaneous drug still receive separate FDA approval?
Yes. FDA approval and Medicare price negotiation serve different purposes. A product may receive separate regulatory approval without automatically qualifying for separate Medicare negotiation treatment.
Will better patient outcomes exempt a reformulation from CMS grouping?
Not automatically. CMS declined to create an exception based on improvements in safety, effectiveness, tolerability, adherence, or delivery. However, these benefits may still be important when evaluating a product’s clinical and commercial value.
What should pharmaceutical brand teams measure when developing follow-on formulations?
Teams should evaluate clinical evidence, administration time, patient experience, staffing requirements, healthcare resource use, and potential access barriers. These measures can help establish meaningful differentiation and support accurate promotional claims.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
